STOCK TITAN

Albert Bourla adds 25 phantom stock units; holdings 731,111

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pfizer (PFE) reported an insider transaction by Chairman & CEO and Director Albert Bourla on 10/15/2025. The filing shows the acquisition of 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan at a price of $24.39 per unit. Following this transaction, Bourla’s derivative holdings total 731,111 phantom stock units, held directly. Each unit represents one phantom share of common stock and will be settled in cash after separation from service; units may be transferred into an alternative investment account at any time.

Positive

  • None.

Negative

  • None.

Insights

Small cash-settled award; administrative and non-dilutive.

Albert Bourla reported acquiring 25 phantom stock units at $24.39 on 10/15/2025, bringing total derivative holdings to 731,111 units. These units are part of a deferred compensation plan.

Because the units are settled in cash after separation, they do not involve share issuance and are typically non-dilutive to common shareholders. The reported quantity is small relative to outstanding equity.

The mechanics and timing are defined by plan terms; actual impact depends on future service and separation events as disclosed in subsequent filings.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOURLA ALBERT

(Last) (First) (Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY

(Street)
NEW YORK NY 10001-2192

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman & CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units SSP (1) 10/15/2025 A 25 (2) (2) Common Stock 25 $24.39 731,111 D
Explanation of Responses:
1. Each unit represents one phantom share of common stock.
2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
/s/ Shanice A. Reid, by power of atty., for Albert Bourla 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pfizer (PFE) report in this Form 4?

Albert Bourla acquired 25 phantom stock units on 10/15/2025 at $24.39 per unit.

How many derivative units does Albert Bourla hold after the transaction?

He holds 731,111 phantom stock units directly after the reported transaction.

What are phantom stock units in this context?

Each unit represents one phantom share of common stock and is settled in cash following separation from service.

Under which plan were the units acquired?

They were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Do these phantom stock units dilute existing Pfizer shareholders?

They are cash-settled, which typically does not result in share issuance and therefore is non-dilutive.

Can the units be moved between investment options?

Yes. The units may be transferred into an alternative investment account at any time.
Pfizer

NYSE:PFE

PFE Rankings

PFE Latest News

PFE Latest SEC Filings

PFE Stock Data

143.68B
5.68B
0.07%
67.08%
1.82%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW YORK